Literature DB >> 32428558

Presynaptic failure in Alzheimer's disease.

Gael Barthet1, Christophe Mulle2.   

Abstract

Synaptic loss is the best correlate of cognitive deficits in Alzheimer's disease (AD). Extensive experimental evidence also indicates alterations of synaptic properties at the early stages of disease progression, before synapse loss and neuronal degeneration. A majority of studies in mouse models of AD have focused on post-synaptic mechanisms, including impairment of long-term plasticity, spine structure and glutamate receptor-mediated transmission. Here we review the literature indicating that the synaptic pathology in AD includes a strong presynaptic component. We describe the evidence indicating presynaptic physiological functions of the major molecular players in AD. These include the amyloid precursor protein (APP) and the two presenilin (PS) paralogs PS1 or PS2, genetically linked to the early-onset form of AD, in addition to tau which accumulates in a pathological form in the AD brain. Three main mechanisms participating in presynaptic functions are highlighted. APP fragments bind to presynaptic receptors (e.g. nAChRs and GABAB receptors), presenilins control Ca2+ homeostasis and Ca2+-sensors, and tau regulates the localization of presynaptic molecules and synaptic vesicles. We then discuss how impairment of these presynaptic physiological functions can explain or forecast the hallmarks of synaptic impairment and associated dysfunction of neuronal circuits in AD. Beyond the physiological roles of the AD-related proteins, studies in AD brains also support preferential presynaptic alteration. This review features presynaptic failure as a strong component of pathological mechanisms in AD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer; Amyloid precursor protein; Presenilin; Presynaptic failure; Presynaptic mechanisms; Tau

Year:  2020        PMID: 32428558     DOI: 10.1016/j.pneurobio.2020.101801

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  12 in total

Review 1.  Super-resolution microscopy: a closer look at synaptic dysfunction in Alzheimer disease.

Authors:  Pranesh Padmanabhan; Andrew Kneynsberg; Jürgen Götz
Journal:  Nat Rev Neurosci       Date:  2021-11-01       Impact factor: 34.870

Review 2.  Conventional and Non-Conventional Roles of Non-Muscle Myosin II-Actin in Neuronal Development and Degeneration.

Authors:  Míriam Javier-Torrent; Carlos A Saura
Journal:  Cells       Date:  2020-08-19       Impact factor: 6.600

3.  Serum D-serine levels are altered in early phases of Alzheimer's disease: towards a precocious biomarker.

Authors:  Luciano Piubelli; Loredano Pollegioni; Valentina Rabattoni; Marco Mauri; Lucia Princiotta Cariddi; Maurizio Versino; Silvia Sacchi
Journal:  Transl Psychiatry       Date:  2021-01-26       Impact factor: 6.222

Review 4.  Proteomic insights into synaptic signaling in the brain: the past, present and future.

Authors:  Yalan Xu; Xiuyue Song; Dong Wang; Yin Wang; Peifeng Li; Jing Li
Journal:  Mol Brain       Date:  2021-02-17       Impact factor: 4.041

5.  Cortical Circuitry and Synaptic Dysfunctions in Alzheimer's Disease and Other Dementias.

Authors:  Federico Ranieri; Alberto Benussi; Mariagiovanna Cantone; Florinda Ferreri; Javier Márquez-Ruiz
Journal:  Neural Plast       Date:  2021-07-29       Impact factor: 3.599

6.  Aplysia Neurons as a Model of Alzheimer's Disease: Shared Genes and Differential Expression.

Authors:  Nicholas S Kron; Lynne A Fieber
Journal:  J Mol Neurosci       Date:  2021-10-18       Impact factor: 3.444

7.  DI-3-n-butylphthalide mitigates stress-induced cognitive deficits in mice through inhibition of NLRP3-Mediated neuroinflammation.

Authors:  Xiu Chen; Juan-Ling He; Xue-Ting Liu; Na Zhao; Fan Geng; Meng-Meng Zhu; Gong-Ping Liu; Qing-Guo Ren
Journal:  Neurobiol Stress       Date:  2022-09-13

Review 8.  Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease.

Authors:  Jesús Burillo; Patricia Marqués; Beatriz Jiménez; Carlos González-Blanco; Manuel Benito; Carlos Guillén
Journal:  Cells       Date:  2021-05-18       Impact factor: 6.600

9.  Novel Monoclonal Antibodies Against Mouse C1q: Characterisation and Development of a Quantitative ELISA for Mouse C1q.

Authors:  Robert A J Byrne; Megan Torvell; Nikoleta Daskoulidou; Dina Fathalla; Eirini Kokkali; Sarah M Carpanini; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2021-05-18       Impact factor: 5.590

10.  Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner.

Authors:  Jean-Charles Lambert; Julien Chapuis; Fanny Eysert; Audrey Coulon; Emmanuelle Boscher; Anaїs-Camille Vreulx; Amandine Flaig; Tiago Mendes; Sandrine Hughes; Benjamin Grenier-Boley; Xavier Hanoulle; Florie Demiautte; Charlotte Bauer; Mikael Marttinen; Mari Takalo; Philippe Amouyel; Shruti Desai; Ian Pike; Mikko Hiltunen; Frédéric Chécler; Mélissa Farinelli; Charlotte Delay; Nicolas Malmanche; Sébastien S Hébert; Julie Dumont; Devrim Kilinc
Journal:  Mol Psychiatry       Date:  2020-11-03       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.